Fusogenic lipid nanoparticles for target cell-specific production of a therapeutic protein
Provided nucleic acid-based expression construct for the target cell-specific production of a therapeutic protein, such as a pro-apoptotic protein, within a target cell, including a target cell that is associated with aging, disease, or other condition, in particular a target cell that is a senescent cell or a cancer cell. Also provided are formulations and systems, including fusogenic lipid nanoparticle (LNP) formulations and systems, for the delivery of nucleic acid-based expression constructs as well as methods for making and using such nucleic acid-based expression constructs, formulations, and systems for reducing, preventing, and/or eliminating the growth and/or survival of a cell, such as a senescent cell and/or a cancer cell, which is associated with aging, disease, or other condition as well as methods for the treatment of aging, disease, or other conditions by the in vivo administration of a formulation, such as a fusogenic LPN formulation, comprising an expression construct for the target cell-specific production of a therapeutic protein, such as a pro-apoptotic protein, in a target cell that is associated with aging, disease, or other condition, in particular a target cell that is a senescent cell or a cancer cell.
1. A lipid-based nanoparticle (LNP) formulation for targeted production of a therapeutic protein within Hall target cells, the LNP formulation comprising:
a. a lipid nanoparticle vector for non-specific delivery of an expression construct to mammalian cells that comprise both the target cells and non-target cells, wherein the lipid nanoparticle vector comprises:
(i) a fusogenic protein;
(ii) 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) at a molar ratio of 22.5-37.5 mole %; and
(iii) 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol (DMG-PEG) at a molar ratio of 3-5 mole %; and
b. the expression construct, wherein the expression construct is configured for preferential production of the therapeutic protein within the target cells, wherein the expression construct comprises:
i. a transcriptional promoter that is activated in response to one or more factors that are preferentially produced within the target cells as compared to the non-target cells; and
ii. a nucleic acid that is operably linked to and under regulatory control of the transcriptional promoter, wherein the nucleic acid encodes the therapeutic protein, wherein the therapeutic protein is capable of reducing, preventing, or eliminating growth or survival of the mammalian cells, wherein the therapeutic protein is produced within the target cells but is not produced in the non-target cells.
2. The LNP formulation of claim 1 , wherein the DOPE or the DMG-PEG is present in the LNP formulation at a concentration ranging from 1 mM to 100 mM.
3. The LNP formulation of claim 1 , wherein the lipid nanoparticle vector further comprises 1,2-dioleoyl-3-dimethylammonium-propane (DODAP).
4. The LNP formulation of claim 3 , wherein the lipid nanoparticle vector comprises the DODAP at a molar ratio of at least 35 mole %.
5. The LNP formulation of claim 1 , wherein the lipid nanoparticle vector comprises the DOPE at a molar ratio of about 30 mole %.
6. The LNP formulation of claim 5 , wherein the lipid nanoparticle vector comprises the DMG-PEG at a molar ratio of about 4 mole %.
7. The LNP formulation of claim 1 , wherein the fusogenic protein is present in the LNP formulation at a concentration ranging from 0.5 μM to 20 μM.
8. The LNP formulation of claim 1 , wherein the fusogenic protein a p14 fusogenic protein that comprises the amino acid sequence of SEQ ID NO: 16.
9. The LNP formulation of claim 1 , wherein the expression construct is present in the LNP formulation at a concentration ranging from 20 μg/mL to 1.5 mg/mL.
10. The LNP formulation of claim 1 , wherein the transcriptional promoter is a p16 transcriptional promoter or a p53 transcriptional promoter.
11. The LNP formulation of claim 1 , wherein the transcriptional promoter is responsive to a factor selected from the group consisting of SP1, ETS1, ETS2, and p53/TP53.
12. The LNP formulation of claim 10 , wherein the transcriptional promoter is a p16INK4a/CDKN2A transcriptional promoter.
13. The LNP formulation of claim 1 , wherein the transcriptional promoter is responsive to an EBF3, O/E-1, Pax-5, E2A, p53, VP16, MLL, HSF1, NF-IL6, NFAT1, AP-1, AP-2, HOX, E2F3, or NF-κB transcription factor.
14. The LNP formulation of claim 13 , wherein the transcriptional promoter is selected from the group consisting of a p21 cip1/waf1 promoter, a p27 kip1 promoter, a p57 kip2 promoter, a TdT promoter, a Rag-1 promoter, a B29 promoter, a Blk promoter, a CD19 promoter, a BLNK promoter, and a λ5 promoter.
15. The LNP formulation of claim 1 , wherein the therapeutic protein is selected from the group consisting of a caspase (Casp), an inducible caspase (iCasp), a self-activating caspase (saCasp), BAX, DFF40, HSV-TK, and cytosine deaminase.
16. The LNP formulation of claim 1 , wherein the therapeutic protein is a caspase selected from the group consisting of a Casp3, a Casp8, and a Casp9.
17. The LNP formulation of claim 1 , wherein the therapeutic protein is Casp9.
18. The LNP formulation of claim 1 , wherein the therapeutic protein is an inducible Casp9 (iCasp9).
19. The LNP formulation of claim 1 , wherein the therapeutic protein is a self-activating Casp9 (saCasp9).
20. The LNP formulation of claim 1 , wherein the fusogenic protein is a p14e15 fusogenic protein that comprises the amino acid sequence of SEQ ID NO: 17.
21. A method of treating a condition in a subject in need thereof, the method comprising administering to the subject one or more lipid-based nanoparticle (LNP) formulations, the one or more LNP formulations comprising:
(a) a first nucleic acid sequence comprising a p16 transcriptional promoter operably linked to a first polynucleotide that encodes a first therapeutic protein; and
(b) a second nucleic acid sequence comprising a p53 transcriptional promoter operably linked to a second polynucleotide that encodes a second therapeutic protein.
22. The method of claim 21 , wherein the first therapeutic protein or the second therapeutic protein is capable of reducing or eliminating growth or survival of target cells in the subject.
23. The method of claim 21 , wherein the first therapeutic protein or the second therapeutic protein is a caspase (Casp), an inducible caspase (iCasp), a self-activating caspase (saCasp), BAX, DFF40, HSV-TK, or cytosine deaminase.
24. The method of claim 21 , wherein the first therapeutic protein or the second therapeutic protein is a Casp3, Casp8, or Casp9.
25. The method of claim 21 , wherein the first therapeutic protein or the second therapeutic protein is Casp9.
26. The method of claim 21 , wherein the first therapeutic protein or the second therapeutic protein is inducible Casp9 (iCasp9).
27. The method of claim 21 , wherein the first therapeutic protein or the second therapeutic protein is self-activating Casp9 (saCasp9).
28. The method of claim 21 , wherein each of the first therapeutic protein and the second therapeutic protein is a caspase (Casp), an inducible caspase (iCasp), or a self-activating caspase (saCasp).